Curanex Pharmaceuticals (CURX) Enterprise Value (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Enterprise Value came in at -$5.0 million in Q4 2025, down 3240.12% YoY from $158374.1 in Q4 2024, and up 14.71% on a QoQ basis from -$5.8 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Enterprise Value (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Enterprise Value data on file, last reported at -$5.0 million in Q4 2025.
- Quarterly Enterprise Value fell 3240.12% year-over-year to -$5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.0 million (down 3240.12% YoY) and the FY2025 annual result came in at -$5.0 million, down 3240.12% from the prior year.
- Enterprise Value improved to -$5.0 million in Q4 2025, from -$5.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$108862.0 in Q2 2025 to a low of -$5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | -5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.97 Mn |
| Sep 30, 2025 | -5.83 Mn |
| Jun 30, 2025 | -108,862.00 |
| Dec 31, 2024 | -148,891.00 |
| Sep 30, 2024 | -244,317.00 |